Biotechnology company Leap Therapeutics Inc (NASDAQ: LPTX) announced on Monday that it has completed patient enrollment in Part B of its DeFianCe study, which is evaluating DKN-01 in combination with bevacizumab and chemotherapy as a second-line treatment for advanced colorectal cancer (CRC). The randomised, controlled Phase 2 study enrolled 188 patients, expanding from an initial target of 130 patients.

The primary endpoint of the study is progression-free survival (PFS), with an additional focus on PFS in patients with left-sided CRC. Secondary endpoints include objective response rate, duration of response and overall survival.

DKN-01, an anti-Dickkopf-1 (DKK1) antibody, is Leap's leading candidate and is being developed for esophagogastric, gynecologic and colorectal cancers.

The results of this study could provide crucial insights into the potential of DKN-01 to improve outcomes for CRC patients, particularly those receiving standard treatments.